Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative…

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024; Potential to be First Approved Treatment for GBS Patients in the…

Related Keywords

,Global Pivotal Program In Geographic Atrophy ,First Half ,First Approved Treatment ,Pivotal Program ,Geographic Atrophy ,Pivotal Trial Using Vision Preservation ,Primary Outcome Measure ,Proof Of Concept Study ,News ,Ggregator ,Reaking News ,Uration ,Media ,